Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01660633 · ClinicalTrials.gov registry record · Phase 2
Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation
A Phase 2 study, sponsored by Acrotech Biopharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 61
- Enrollment target
NCT01660633 is a Phase 2 study that has completed, run by Acrotech Biopharma. The registered enrollment target is 61 participants.
The verdict
NCT01660633, a Phase 2 study, has completed, sponsored by Acrotech Biopharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this trial is to confirm the safety and efficacy of high-dose Melphalan HCL for Injection (Propylene Glycol-Free) as a myeloablative conditioning regimen in multiple myeloma patients (MM) undergoing autologous transplantation.
Interventions
- DRUG High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)
- OTHER Autologous Transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01660633
The ClinicalTrials.gov registry entry for NCT01660633 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acrotech Biopharma, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which High-Dose Melphalan HCL for Injection (Propylene Glycol-Free) is the first listed.
NCT01660633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01660633 about?
NCT01660633 is a clinical study titled "Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation". The purpose of this trial is to confirm the safety and efficacy of high-dose Melphalan HCL for Injection (Propylene Glycol-Free) as a myeloablative conditioning regimen in multiple myeloma patients (MM) undergoing autologous transplantation.
What is the current status of trial NCT01660633?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2012-12. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01660633?
The interventions under investigation include: High-Dose Melphalan HCL for Injection (Propylene Glycol-Free) (DRUG), Autologous Transplantation (OTHER).
Who is sponsoring clinical trial NCT01660633?
This trial is sponsored by Acrotech Biopharma, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.